Arsanis Inc’s (ASNS) Quiet Period Set To End Tomorrow

Arsanis’ (NASDAQ:ASNS) quiet period will end on Tuesday, December 26th. Arsanis had issued 4,000,000 shares in its initial public offering on November 16th. The total size of the offering was $40,000,000 based on an initial share price of $10.00. During Arsanis’ quiet period, insiders and underwriters that worked on the IPO are restricted from issuing any research reports or earnings estimates for the company because of SEC regulations. Following the expiration of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

A number of equities research analysts have issued reports on ASNS shares. Cowen started coverage on Arsanis in a research report on Monday, December 11th. They issued an “outperform” rating on the stock. Citigroup started coverage on Arsanis in a research report on Monday, December 11th. They issued a “buy” rating and a $27.00 price target on the stock. Finally, Piper Jaffray Companies started coverage on Arsanis in a research report on Monday, December 11th. They issued an “overweight” rating and a $23.00 price target on the stock.

Shares of Arsanis (NASDAQ:ASNS) opened at $12.70 on Monday. The stock has a market capitalization of $138.50 and a PE ratio of -6.20. Arsanis has a 12-month low of $10.40 and a 12-month high of $19.73.

In other Arsanis news, major shareholder Polaris Venture Management Co. bought 500,000 shares of the business’s stock in a transaction dated Monday, November 20th. The shares were acquired at an average price of $10.00 per share, with a total value of $5,000,000.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Tillman U. Gerngross bought 200,000 shares of the business’s stock in a transaction dated Monday, November 20th. The shares were acquired at an average cost of $10.00 per share, for a total transaction of $2,000,000.00. The disclosure for this purchase can be found here.

ILLEGAL ACTIVITY NOTICE: “Arsanis Inc’s (ASNS) Quiet Period Set To End Tomorrow” was originally reported by Community Financial News and is owned by of Community Financial News. If you are accessing this report on another publication, it was copied illegally and republished in violation of United States and international copyright and trademark legislation. The original version of this report can be read at https://www.com-unik.info/2017/12/25/arsanis-incs-asns-quiet-period-set-to-end-tomorrow.html.

Arsanis Company Profile

Arsanis, Inc is a biopharmaceutical company. The Company is focused on the discovering and developing monoclonal antibodies (mAbs) for the targeted immunotherapy of serious infections. The Company’s mAbs focus on specific pathogens and pathogenic processes. Its product pipeline includes ASN100, ASN200, ASN300, ASN400 and ASN500.

Receive News & Ratings for Arsanis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arsanis and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit